Literature DB >> 14969479

A new dose-finding design for bivariate outcomes.

Anastasia Ivanova1.   

Abstract

For some drugs, toxicity events lead to early termination of treatment before a therapeutic response is observed. That is, there are three possible outcomes: toxicity (therapeutic response unknown), therapeutic response without toxicity, and no response with no toxicity. The optimal dose is the dose that maximizes the probability of the joint event, response, and no toxicity. The optimal safe dose is the dose, from among the doses with toxicity rate less than the maximum tolerable level, that maximizes the probability of response and no toxicity. We present a new sequential design to maximize the number of subjects assigned in the neighborhood of the optimal safe dose in a dose-finding trial with two outcomes.

Entities:  

Mesh:

Year:  2003        PMID: 14969479     DOI: 10.1111/j.0006-341x.2003.00115.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  23 in total

1.  Integrating the escalation and dose expansion studies into a unified Phase I clinical trial.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Contemp Clin Trials       Date:  2016-07-05       Impact factor: 2.226

2.  Design considerations for dose-expansion cohorts in phase I trials.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

3.  Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach.

Authors:  Anastasia Ivanova; Se Hee Kim
Journal:  Biometrics       Date:  2008-05-13       Impact factor: 2.571

4.  Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.

Authors:  Tze L Lai; Philip W Lavori
Journal:  Stat Biosci       Date:  2011-12

5.  Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

Authors:  Peter F Thall
Journal:  Stat Sci       Date:  2010-05       Impact factor: 2.901

6.  Sequential monitoring of Phase I dose expansion cohorts.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Stat Med       Date:  2016-02-07       Impact factor: 2.373

7.  Statistical justification of expansion cohorts in phase 1 cancer trials.

Authors:  Ali A Mokdad; Xian-Jin Xie; Hong Zhu; David E Gerber; Daniel F Heitjan
Journal:  Cancer       Date:  2018-07-05       Impact factor: 6.860

8.  Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.

Authors:  Yisheng Li; B Nebiyou Bekele; Yuan Ji; John D Cook
Journal:  Stat Med       Date:  2008-10-30       Impact factor: 2.373

9.  A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies.

Authors:  Jay Bartroff; Tze Leung Lai; Balasubramanian Narasimhan
Journal:  Stat Med       Date:  2014-02-27       Impact factor: 2.373

10.  A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations.

Authors:  José L Jiménez; Sungjin Kim; Mourad Tighiouart
Journal:  Biom J       Date:  2020-03-09       Impact factor: 2.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.